Skip to main content

Advertisement

Table 5 Diagnostic advantages of serum sCD40L for differentiation of PDAC from non-cancer in cases where the levels of CA19-9 are inappropriate *

From: Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

  Low-serum CA 19–9 subjects High-serum CA 19–9 subjects
Cut-off value Sensitivity Specificity Cut-off value Sensitivity Specificity
sCD40L (ng/ml) 20000 80.0% 86.7% 20000 77.0% 85.0%
  1. Sensitivity and specificity of serum sCD40L to differentiate PDAC from non-cancer in subjects with low-serum (≤40 ng/mL) or high-serum CA19-9 (>40 ng/mL) levels when serum CA19-9 does not correspond to a disease entity.
  2. sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; PDAC, pancreatic ductal adenocarcinoma.
  3. * This means that the cases when CA19-9 are inappropriately high in normal subjects or inappropriately low in patients with PDAC in the validation dataset.